Use of Recombinant Activated Factor VII in Primary Postpartum Hemorrhage: The Northern European Registry 2000-2004

Alfirević, Z̄arko; Elbourne, Diana; Pavord, Sue; Bolte, A.; Geijn, Herman van; Mercier, Fabien; Ahonen, Jouni; Bremme, Katarina; Bødker, Birgit; Magnúsdóttir, Ebba Margrét; Salvesen, K. Å.; Prendiville, Walter; Truesdale, Ann; Clemens, Felicity; Piercy, Deborah; Gyte, Gillian ML

doi:10.1097/01.aoa.0000326387.35240.69

Cited by 35 publications

(69 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…64 Hemostasis is achieved by direct activation of platelets, the tenase complex, and tissue factor-mediated coagulation. It is effective in up to 80% of cases 65 but thrombotic events have been observed in 2.5% of treated cases, 66 including deep venous thrombosis, pulmonary embolism, cerebral thrombosis, and myocardial infarction. Data from trials with rVIIa, outside the setting of pregnancy, also warned of heightened thrombotic risk, leading the manufacturers to advise against this offlicense use of rFVIIa (Novonordisk SPC).…”

Section: Recombinant Fviiamentioning

confidence: 99%

How I treat postpartum hemorrhage

Pavord

Maybury

2015

Blood

View full text Add to dashboard Cite

Worldwide, ∼800 women die every day from preventable causes related to pregnancy or childbirth. The single most common cause is severe bleeding, which can kill a healthy woman within hours if care is substandard or delayed. Improved antenatal practices have led to the early identification of at-risk women and modern technology and new techniques have enabled effective management strategies so that now, in the western world, most of the morbidity and mortality arises from those cases which occur unexpectedly and could not have been predicted. Prompt and effective management and multidisciplinary involvement is paramount to save the lives of these women. We use a case report to illustrate and discuss the main elements of management of this condition.

show abstract

Section: Recombinant Fviiamentioning

confidence: 99%

How I treat postpartum hemorrhage

Pavord

Maybury

2015

Blood

View full text Add to dashboard Cite

show abstract

“…Despite controversial evidence and lack of prospective randomised controlled trials (RCT) and before an emergency hysterectomy, an individual treatment decision with rFVIIa might be made with a dose of 90 μg/kg BW [59,60] if the patient has been adequately treated with all other mentioned therapeutic options, these other options were not sufficiently effective and the patient's family planning is not complete [17]. Due to an increased risk of (arterial) thromboembolism [61], rFVIIa should only be an ultima ratio therapy.…”

Section: Haemostasis and Coagulation Managementmentioning

confidence: 99%

Peripartum Haemorrhage: Haemostatic Aspects of the New German PPH Guideline

Lier

Heymann

Korte

et al. 2017

Transfus Med Hemother

View full text Add to dashboard Cite

Peripartum haemorrhage remains one of the main causes of maternal mortality world-wide. The German, Austrian and Swiss Societies of Gynaecology and Obstetrics have updated the current guidelines for the treatment of peripartum haemorrhage together with the German Society of Anaesthesiology and Intensive Care Medicine and the Society of Thrombosis and Haemostasis Research. The recommendations have been the result of a thorough review of the available scientific literature and a consensus process involving all members of the guideline group. A key element of the anaesthesiological and haemostatic management is the development of a multidisciplinary standard operating procedure combining surgical as well as medical and haemostatic treatments depending on the severity of bleeding. The guideline underscores the value of clinical and laboratory diagnostics of peripartum haemorrhage as early as possible, even pre-emptively. This allows for an early identification of causes of bleeding and a specific treatment. The guideline comprises evidence-based recommendations for the use of uterotonics, tranexamic acid and blood products such as factor concentrates, fresh frozen plasma, platelet concentrates, packed red blood cells, recombinant activated factor VII and desmopressin. In addition, recommendations for blood conservation strategies involving the use of cell salvage, permissive hypotension and transfusion triggers are given.

show abstract

“…Two (1Á9%) non-fatal thromboembolic complications were reported considered likely to be linked to rFVIIa . The Northern Europe FVIIa in Obstetric Haemorrhage (NEFOH) reported use in 92 women with obstetric haemorrhage from 531 maternity units in nine countries (Alfirevic et al, 2007). Again the majority of women (82%) received a single dose of rFVIIa and it was reported to improve bleeding in 77 women (83%; Alfirevic et al, 2007).…”

Section: Recombinant Fviia and Other Factor Concentrates In Mohmentioning

confidence: 99%

How we manage the haematological aspects of major obstetric haemorrhage

2013

View full text Add to dashboard Cite

SummaryMajor obstetric haemorrhage (MOH) remains an important medical challenge worldwide, contributing to significant maternal morbidity and mortality. Prompt and appropriate management is essential if we are to improve outcomes and reduce substandard care that may result in adverse consequences. This review describes the current understanding of the pathophysiological aspects of MOH together with the principles of transfusion and haemostatic therapy, with emphasis on a coordinated multidisciplinary approach. We also highlight the current lack of evidence available from randomized controlled trials to inform best practice and the need to prioritize research in this key clinical area.

show abstract

Use of Recombinant Activated Factor VII in Primary Postpartum Hemorrhage: The Northern European Registry 2000-2004

Cited by 35 publications

References 3 publications

How I treat postpartum hemorrhage

How I treat postpartum hemorrhage

Peripartum Haemorrhage: Haemostatic Aspects of the New German PPH Guideline

How we manage the haematological aspects of major obstetric haemorrhage

Contact Info

Product

Resources

About